| Period | Response Status | |||
| (months) | Optimal | Sub-optimal | Failure | Warnings |
| 3 | CHR At least minor CyR BCR-ABL ≤ 10% by qRT-PCR or PCyR | No CyR NA | | NA |
| 6 | At least PCyR NA | | No CyR NA | NA |
| 12 | CCyR | PCyR* | | NA |
| 18 | MMR CCyR | | | NA |
| At any time during treatment* | Stable or improving MMR | Loss of MMR BCR-ABL KD mutations (still sensitive to imatinib) | Loss of CHR Loss of CCyR BCR-ABL KD mutations (poorly sensitive to imatinib) CCA/Ph+** | Increase in transcript levels CCA/Ph− |